Trial Profile

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mahatinib (Primary)
Indications Prostate cancer
Focus Adverse reactions; First in man
Acronyms PHAROS
Sponsors TechnoGenesys

Most Recent Events

05 Sep 2025 Planned primary completion date changed from 30 Mar 2026 to 30 Dec 2026.
05 Sep 2025 Planned initiation date changed from 30 Mar 2025 to 30 Sep 2025.
06 Apr 2025 Planned number of patients changed from 30 to 40.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com